Alan Shuldiner, M.D.
Vice President, Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc., USA
John Whitehurst Professor of Medicine, University of Maryland School of Medicine, USA
Dr. Shuldiner founded and directs the Discovery Research Investigating Founder Population Traits (DRIFT) Program at the Regeneron Genetics Center. Their goals are to (i) catalogue population-specific allelic architecture; (ii) understand the biological and functional consequences of specific mutations identified; and (iii) share and establish best practice approaches to relieve disease burden in these populations. In his part-time role at the University of Maryland, Dr. Shuldiner is Associate Dean and Director of the Program for Personalized and Genomic Medicine whose mission is to is to advance discovery in genomics and other “omic” sciences. Dr. Shuldiner’s research applies high-throughput sequencing technologies to better understand human health and disease toward the identification and development of novel therapeutic targets and preventive therapies for diseases of unmet need. He also works to implement evidence-based genomic medicine and pharmacogenetics into patient care.